Advertisement
Organisation › Details
Inserm Transfert Initiative (ITI)
Created in 2005, Inserm Transfert Initiative is a seed-capital company with € 39.7 M capital, further to its second fund raising in 2012. It focuses on providing seed capital for innovative young companies in the biomedical field. Inserm Transfert Initiative supports biotech entrepreneurs in the early stages of their companies' development. Its current shareholders are BPI France, Inserm Transfert SA, AbbVie, Boehringer Ingelheim Venture Fund, GlaxoSmithKline, Ipsen, LFB, MSD (Merck & Co), Natixis Venture Selection, Pfizer, Sanofi, SHAM, Shire, Sofinnova Partners. *
Start | 2005-01-01 established | |
Group | France (govt) | |
Industry | venture capital | |
Industry 2 | LIFE SCIENCES | |
Person | Tharaud, Cécile (INSERM 201403– CEO of Inserm Transfert Initiative before CEO of Inserm Transfert) | |
Region | Paris | |
Country | France | |
Street | 7 rue Watt | |
City | 75013 Paris | |
Tel | +33-1-5503-0100 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: | ||
Record changed: 2024-02-12 |
Advertisement
More documents for France (govt)
- [1] SurgeCare SAS. (3/27/24). "Press Release: Surge Announces Closing of a €7.5 Million Fundraising Round to Decrypt the Immune System and Transform Precision Medicine". Paris....
- [2] Global Bioenergies S.A.. (10/4/23). "Press Release: French Government Awards Global Bioenergies €16.4 Million to Help Fund Construction of the World’s First Biosourced Isobutene Plant". Évry....
- [3] EverImmune. (9/19/23). "Press Release: EverImmune Secures €3.5 Million in Financing from Bpifrance". Villejuif....
- [4] Biper Therapeutics SAS. (2/14/23). "Press Release: Biper Therapeutics Raises €1.25 Million in Seed Funding to Develop First-in-Class Small Molecules to Treat Gastrointestinal Cancers". Strasbourg....
- [5] Theranexus S.A.. (10/20/22). "Press Release: Theranexus and Inserm Transfert Sign a Strategic Alliance to Identify Advanced Therapy Drug Candidates for Rare Neurological Diseases". Lyon....
- [6] AdBio Partners SAS. (5/3/22). "Press Release: AdBio Partners Welcomes Inserm Transfert as Investor in Second Fund – AFB Fund II". Paris....
- [7] Hemerion Therapeutics SAS. (4/14/22). "Press Release: Hemerion Therapeutics successfully raises over €3.5 million: a new hope for the treatment of brain cancer". Villeneuve d’Ascq....
- [8] SeaBeLife SAS. (3/14/22). "Press Release: SeaBeLife Receives Close to €1.4M Deep Tech Financing from Bpifrance". Roscoff....
- [9] Cell-Easy. (2/28/22). "Press Release: The OPTI-STEM Consortium Led by CDMO Cell-Easy Receives €7M from the French Government and Bpifrance and €800,000 from the Occitanie Region to Democratize Access to Cell Therapy in France and Europe". Toulouse, La...
- [10] Amolyt Pharma SAS. (2/4/22). "Press Release: Amolyt Pharma Selected for the French Tech 120 Program". Lyon & Cambridge, MA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top